NBM

NatureWise Biotech & Medicals (NBM) is a clinical-stage biotechnology company headquartered in Taiwan, specializing in the discovery and development of small molecule drugs for oncology and neurodegenerative conditions. The company's primary focus is on its lead candidate, NBM-BMX, a highly selective Histone Deacetylase 8 (HDAC8) inhibitor designed to cross the blood-brain barrier for the treatment of glioblastoma multiforme. NBM is also advancing research into the application of its HDAC8 inhibitors for Alzheimer's disease, aiming to address significant unmet medical needs in brain health. Additionally, the company maintains a pipeline of candidates targeting metabolic disorders and other solid tumors. NatureWise leverages a combination of natural product chemistry and modern drug design to identify novel therapeutic scaffolds.